Aileron Therapeutics Inc. (NASDAQ: ALRN) is a bio pharmaceutical company that focuses on the development of novel oncology drugs. The company’s recently developed ALRN-6924 treatment is in Phase 2A clinical trials for the treatment of advanced solid tumors. The company is also developing leukemia treatments which are currently in Phase 1B testing.
Analysts have been upbeat about the company’s future, believing that its novel tumor treatments will be major revenue drivers in the coming years. The stock is priced at a bargain today, having closed at just under $1 in yesterday’s session. The average target consensus of $4.11 suggests that investors who buy now will generate significant returns from this stock in the next year.
Aileron pharmaceutical is well-funded although it is yet to generate a profit. It generated a positive EBITDA growth of 5.94% in the previous fiscal year. This stock is all about potential. Like many of the best alternative bargain picks, speculation is high. With a modest investment in a well-diversified portfolio, this option is worth considering, especially with the significant price upside that analysts expect to come.
- 1 Year Price Growth: 31%
- YTD Price Growth: 59%
- 3 Month Price Growth: -24.55%
All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.